DOI: 10.1128/AAC.01221-18
Article Information
PubMed
Published By
History
- Received June 7, 2018
- Returned for modification July 17, 2018
- Accepted September 12, 2018
- Published online November 26, 2018.
Copyright & Usage
Copyright © 2018 Scangarella-Oman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Article Versions
- Accepted Manuscript version (September 24, 2018).
- You are viewing the most recent version of this article.
Author Information
- Nicole E. Scangarella-Omana,
- Mohammad Hossaina,
- Paula B. Dixonb,
- Karen Ingrahama,
- Sharon Mina,
- Courtney A. Tiffanya,
- Caroline R. Perrya,
- Aparna Raychaudhuria,
- Etienne F. Dumonta,
- Jianzhong Huanga,
- Edward W. Hook IIIb and
- Linda A. Millera*
- aGlaxoSmithKline, Upper Providence, Pennsylvania, USA
- bUniversity of Alabama at Birmingham, Birmingham, Alabama, USA
- Address correspondence to Nicole E. Scangarella-Oman, Nicole.E.Scangarella-Oman{at}gsk.com, or Courtney A. Tiffany, courtney.a.tiffany{at}gsk.com.
↵* Present address: Linda A. Miller, CMID Pharma Consulting, LLC, Dresher, PA.
Citation Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, Perry CR, Raychaudhuri A, Dumont EF, Huang J, Hook EW, III, Miller LA. 2018. Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Antimicrob Agents Chemother 62:e01221-18. https://doi.org/10.1128/AAC.01221-18.
